Review



luminescent proximity homogeneous assay alpha screening  (Biacore)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Biacore luminescent proximity homogeneous assay alpha screening
    Luminescent Proximity Homogeneous Assay Alpha Screening, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/alpha+assay+homogeneous+luminescent+proximity+screening/us12624077-144-38-34
    Average 86 stars, based on 1 article reviews
    luminescent proximity homogeneous assay alpha screening - by Bioz Stars, 2026-11
    86/100 stars

    Images

    Related Articles

    Binding Assay:

    Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
    Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as ALPHA Screen (Amplified Luminescent Proximity Homogeneous Assay), a BIACORE method using the surface plasmon resonance (SPR) phenomena, and such (Proc. ..

    Activity Assay:

    Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
    Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as ALPHA Screen (Amplified Luminescent Proximity Homogeneous Assay), a BIACORE method using the surface plasmon resonance (SPR) phenomena, and such (Proc. ..

    FACS:

    Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
    Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as ALPHA Screen (Amplified Luminescent Proximity Homogeneous Assay), a BIACORE method using the surface plasmon resonance (SPR) phenomena, and such (Proc. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
    Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as ALPHA Screen (Amplified Luminescent Proximity Homogeneous Assay), a BIACORE method using the surface plasmon resonance (SPR) phenomena, and such (Proc. ..

    Amplification:

    Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
    Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as ALPHA Screen (Amplified Luminescent Proximity Homogeneous Assay), a BIACORE method using the surface plasmon resonance (SPR) phenomena, and such (Proc. ..

    SPR Assay:

    Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB
    Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as ALPHA Screen (Amplified Luminescent Proximity Homogeneous Assay), a BIACORE method using the surface plasmon resonance (SPR) phenomena, and such (Proc. ..



    Similar Products

    86
    Biacore luminescent proximity homogeneous assay alpha screening
    Luminescent Proximity Homogeneous Assay Alpha Screening, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/alpha+assay+homogeneous+luminescent+proximity+screening/us12624077-144-38-34
    Average 86 stars, based on 1 article reviews
    luminescent proximity homogeneous assay alpha screening - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Biacore alpha screen
    Alpha Screen, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/alpha+screen/us12624089-962-50-58
    Average 86 stars, based on 1 article reviews
    alpha screen - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Sebia Inc α thalassemia screening
    α Thalassemia Screening, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/screening+thalassemia+%CE%B2/pm40890560-195-1-3
    Average 86 stars, based on 1 article reviews
    α thalassemia screening - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    99
    Advisains alpha-glucosidase inhibitor screening kit (colorimetric) 100 tests
    Alpha Glucosidase Inhibitor Screening Kit (Colorimetric) 100 Tests, supplied by Advisains, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/alpha-Glucosidase+Inhibitor+Screening+Kit+(Colorimetric)+100+tests/custom%40ab284520%4040582127
    Average 99 stars, based on 1 article reviews
    alpha-glucosidase inhibitor screening kit (colorimetric) 100 tests - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    93
    Addgene inc crispr screen
    Crispr Screen, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/PKG+I+alpha+dNPS+(Plasmid+%2316391)/pm40435412-301-0-30
    Average 93 stars, based on 1 article reviews
    crispr screen - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    Thermo Fisher alpha screen® microplate reader
    Alpha Screen® Microplate Reader, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/10__1016_slash_j__molstruc__2024__140352-338-16-22
    Average 90 stars, based on 1 article reviews
    alpha screen® microplate reader - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    93
    BPS Bioscience tnfr2 tnf α
    Tnfr2 Tnf α, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/TNFR2%3ATNF-alpha%5BBiotinylated%5D+Inhibitor+Screening+Assay+Kit/pm39854441-170-0-7
    Average 93 stars, based on 1 article reviews
    tnfr2 tnf α - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    ACROBiosystems cd47:sirp alpha biotinylated inhibitor screening elisa assay pair #ep-102
    a Mechanism of action of conventional aEGFRvIII CAR T cell monotherapy in GBM. b Proposed aEGFRvIII-SGRP CAR T cell combination therapy whereby SGRP-mediated <t>CD47</t> blockade induces phagocytic modulation of GAMs in the context of EGFRvIII-heterogenous GBM and its immunosuppressive iTME. c Outline of the SGRP engineering strategy, including specific AA substitutions to the endogenous human SIRPγ-V1 sequence and addition of an N-terminal IL-2 signal sequence (IL2sig) leading to constitutive SGRP secretion. d Polycistronic lentiviral constructs encoding mCherry (mC)-labeled aCD19 CAR or aEGFRvIII CAR under the control of EF1A promoter ± SGRP secretion. e Workflow of CAR T cell production applied throughout the study. a – e Created in BioRender. Hutter, G. (2022) BioRender.com/u48r093. Representative plots of CAR:target protein binding by aCD19 CAR T cells ( f ) or aEGFRvIII CAR T cells ( g ) to CAR-bound <t>biotinylated</t> (bt)-CD19 (top plots) or bt-EGFRvIII (bottom plots); n = 2 healthy donors (HDs) assessed per CAR. h TATA-box binding protein (TBP)-normalized expression of mCherry and SGRP detected by real-time quantitative PCR (RT-qPCR) in aEGFRvIII CAR or aEGFRvIII-SGRP CAR T cells, showing mCherry expression in CARs transduced with either construct and SGRP expression specifically in aEGFRvIII-SGRP CARs; n = 4 HDs. Data are presented as scatter plots with mean values ± SD. Statistical differences were assessed by two-sided unpaired t tests with Welch’s correction. i Differentially secreted proteins in aEGFRvIII-SGRP CAR- vs aEGFRvIII CAR-conditioned media, highlighting the presence of SGRP exclusively in aEGFRvIII-SGRP CAR; n = 2 HDs. Mean SGRP expression: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$-\log 10{{{\rm{qValue}}}}/\log 2{{{\rm{foldchange}}}}=8.60/6.65$$\end{document} − log 10 qValue / log 2 foldchange = 8.60 / 6.65 . Source data are provided as a Source Data file. Source data for ( i ) are provided as Supplementary Data .
    Cd47:Sirp Alpha Biotinylated Inhibitor Screening Elisa Assay Pair #Ep 102, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alpha+screen/his+cd47/pmc11550474-631-8-17
    Average 90 stars, based on 1 article reviews
    cd47:sirp alpha biotinylated inhibitor screening elisa assay pair #ep-102 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    a Mechanism of action of conventional aEGFRvIII CAR T cell monotherapy in GBM. b Proposed aEGFRvIII-SGRP CAR T cell combination therapy whereby SGRP-mediated CD47 blockade induces phagocytic modulation of GAMs in the context of EGFRvIII-heterogenous GBM and its immunosuppressive iTME. c Outline of the SGRP engineering strategy, including specific AA substitutions to the endogenous human SIRPγ-V1 sequence and addition of an N-terminal IL-2 signal sequence (IL2sig) leading to constitutive SGRP secretion. d Polycistronic lentiviral constructs encoding mCherry (mC)-labeled aCD19 CAR or aEGFRvIII CAR under the control of EF1A promoter ± SGRP secretion. e Workflow of CAR T cell production applied throughout the study. a – e Created in BioRender. Hutter, G. (2022) BioRender.com/u48r093. Representative plots of CAR:target protein binding by aCD19 CAR T cells ( f ) or aEGFRvIII CAR T cells ( g ) to CAR-bound biotinylated (bt)-CD19 (top plots) or bt-EGFRvIII (bottom plots); n = 2 healthy donors (HDs) assessed per CAR. h TATA-box binding protein (TBP)-normalized expression of mCherry and SGRP detected by real-time quantitative PCR (RT-qPCR) in aEGFRvIII CAR or aEGFRvIII-SGRP CAR T cells, showing mCherry expression in CARs transduced with either construct and SGRP expression specifically in aEGFRvIII-SGRP CARs; n = 4 HDs. Data are presented as scatter plots with mean values ± SD. Statistical differences were assessed by two-sided unpaired t tests with Welch’s correction. i Differentially secreted proteins in aEGFRvIII-SGRP CAR- vs aEGFRvIII CAR-conditioned media, highlighting the presence of SGRP exclusively in aEGFRvIII-SGRP CAR; n = 2 HDs. Mean SGRP expression: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$-\log 10{{{\rm{qValue}}}}/\log 2{{{\rm{foldchange}}}}=8.60/6.65$$\end{document} − log 10 qValue / log 2 foldchange = 8.60 / 6.65 . Source data are provided as a Source Data file. Source data for ( i ) are provided as Supplementary Data .

    Journal: Nature Communications

    Article Title: Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

    doi: 10.1038/s41467-024-54129-w

    Figure Lengend Snippet: a Mechanism of action of conventional aEGFRvIII CAR T cell monotherapy in GBM. b Proposed aEGFRvIII-SGRP CAR T cell combination therapy whereby SGRP-mediated CD47 blockade induces phagocytic modulation of GAMs in the context of EGFRvIII-heterogenous GBM and its immunosuppressive iTME. c Outline of the SGRP engineering strategy, including specific AA substitutions to the endogenous human SIRPγ-V1 sequence and addition of an N-terminal IL-2 signal sequence (IL2sig) leading to constitutive SGRP secretion. d Polycistronic lentiviral constructs encoding mCherry (mC)-labeled aCD19 CAR or aEGFRvIII CAR under the control of EF1A promoter ± SGRP secretion. e Workflow of CAR T cell production applied throughout the study. a – e Created in BioRender. Hutter, G. (2022) BioRender.com/u48r093. Representative plots of CAR:target protein binding by aCD19 CAR T cells ( f ) or aEGFRvIII CAR T cells ( g ) to CAR-bound biotinylated (bt)-CD19 (top plots) or bt-EGFRvIII (bottom plots); n = 2 healthy donors (HDs) assessed per CAR. h TATA-box binding protein (TBP)-normalized expression of mCherry and SGRP detected by real-time quantitative PCR (RT-qPCR) in aEGFRvIII CAR or aEGFRvIII-SGRP CAR T cells, showing mCherry expression in CARs transduced with either construct and SGRP expression specifically in aEGFRvIII-SGRP CARs; n = 4 HDs. Data are presented as scatter plots with mean values ± SD. Statistical differences were assessed by two-sided unpaired t tests with Welch’s correction. i Differentially secreted proteins in aEGFRvIII-SGRP CAR- vs aEGFRvIII CAR-conditioned media, highlighting the presence of SGRP exclusively in aEGFRvIII-SGRP CAR; n = 2 HDs. Mean SGRP expression: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$-\log 10{{{\rm{qValue}}}}/\log 2{{{\rm{foldchange}}}}=8.60/6.65$$\end{document} − log 10 qValue / log 2 foldchange = 8.60 / 6.65 . Source data are provided as a Source Data file. Source data for ( i ) are provided as Supplementary Data .

    Article Snippet: Experiments involving ELISA assays were performed using a CD47:SIRP alpha Biotinylated Inhibitor Screening ELISA Assay Pair (#EP-102, ACROBiosystems, USA) or Human SIRP alpha DuoSet ELISA (#DY4546-05, R&D Systems, USA).

    Techniques: Sequencing, Construct, Labeling, Control, Protein Binding, Binding Assay, Expressing, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Transduction